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In their most recent work, Giamarellos-Bourboulis and 
colleagues examine sepsis-related immune dysfunction 
by assessing the proinﬂ  ammatory cytokine production 
capacity in septic patients and healthy volunteers follow-
ing ex vivo stimulation [1]. A critical examination of their 
article not only reveals new insights into the possible 
mechanisms underlying sepsis-related immune system 
dysfunction, but also highlights the diﬃ   culties inherent 
in this line of inquiry. Th  e authors report that septic 
patients’ isolated leukocytes produced lower amounts of 
the proinﬂ   ammatory cytokines IL-1β, IL-6 and, to a 
lesser extent, TNFα when stimulated within 24 hours of 
Gram-negative sepsis onset. Interestingly, greater 
severity of sepsis was correlated with a greater degree of 
impairment. Results were similar in healthy volunteers 
challenged with lipopolysaccharide, indicating an early 
shift to an immune-suppressed phenotype following 
systemic inﬂ  ammation.
In our current understanding, an early anti-inﬂ  amma-
tory phenotype following close on the heels of a severe 
inﬂ  ammatory challenge (sepsis, trauma, burn injury, and 
so forth) acts as a counterweight to the systemic 
inﬂ  ammatory response syndrome and restores immune 
homeostasis [2]. When short-lived and self-limited, this 
anti-inﬂ  ammatory surge is best termed the compensatory 
anti-inﬂ  ammatory response syndrome (CARS). In some 
patients, however, CARS is pathologically exaggerated 
and prolonged (beyond 48 hours). Th   is persistent state – 
known as immunoparalysis – is associated with increased 
rates of nosocomial sepsis, multiorgan dysfunction syn-
drome and death in critically ill patients [3-5]. Although 
the features are similar, the distinction between CARS 
and immunoparalysis is important when contemplating 
therapy. Th   e issue is one of timing: to reverse physiologic 
CARS too early in the course of illness risks further 
inﬂ   ammatory insult. Th  e literature, however, suggests 
that pathologic immunoparalysis is reversible, to the 
beneﬁ  t of the patient, without iatrogenic hyperinﬂ  am  ma-
tion [6-8].
Although the identiﬁ   cation of immunoparalysis, its 
impact on outcome, and its potential reversibility are 
becoming increasingly understood, relatively little is 
known about the cellular and molecular mechanisms 
driving the process. Previous authors have investigated 
the mechanisms of immunoparalysis at the transcriptome 
level [9-11]. Th   is current report makes the case for post-
translational forces as well. In addition to ex vivo cytokine 
production, Giamarellos-Bourboulis and colleagues 
examined levels of caspase-1, a protease that cleaves pro-
IL-1β into its active form. In their septic patients, 
reduced IL-1β production capacity was associated with 
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Sepsis is now understood to aff  ect a variety of changes 
in the host, chief among them being alterations in 
immune system function. Proper immune function 
involves a competent proinfl  ammatory response 
to stimuli as well as a regulated counteracting 
force to restore homeostasis and prevent systemic 
infl  ammation and organ dysfunction. Broad-spectrum 
suppression of the infl  ammatory response has not 
been shown to be benefi  cial for patients suff  ering 
from septic disease. In fact, sepsis-related immune 
suppression has become increasingly recognized 
as an important contributor to late morbidity and 
mortality in the critically ill. Giamarellos-Bourboulis and 
colleagues detail the impaired ability of septic patients 
to produce proinfl  ammatory cytokines upon ex vivo 
stimulation, and introduce altered caspase-1 activity 
as potentially contributory to this process. Proper 
understanding of the cellular and molecular events 
resulting in immune suppression following sepsis is 
important in the identifi  cation of new strategies for 
treatment and the ideal timing of therapy.
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© 2011 BioMed Central Ltdmarkedly diminished caspase-1 levels. In their healthy 
volunteers, injection with lipopolysaccharide  resulted in 
lower levels of caspase-1, as well as impaired production 
of IL-1β. Heretofore, immunoparalysis research has 
largely centered on the canonical proinﬂ  ammatory 
cytokine TNFα. (Indeed, assessing ex vivo lipopoly  sac-
charide-induced TNFα production capacity by isolated 
monocytes is a commonly used method for diagnosing 
immunoparalysis [2].) By introducing altered IL-1β 
biology as a contributory process in the development of 
CARS/immunoparalysis, the authors lay the ground work 
for additional avenues of research into the cause(s) or 
diagnosis of these conditions. Further research is 
necessary to conﬁ   rm a causal link between impaired 
caspase-1 function and IL-1β production. It is also 
important to note that, like TNFα, IL-1β is one of myriad 
proinﬂ  ammatory cytokines whose production and regu-
la  tion may be altered in immunoparalysis.
Despite these new and interesting contributions, 
placing the current work by Giamarellos-Bourboulis and 
colleagues into proper context is complicated by their 
study design. Th  e early (within 24 hours) sampling 
window, without additional longitudinal samples, makes 
it impossible to distinguish patients with physiologic 
CARS from those with pathologic immunoparalysis. 
Previous evidence has shown that only patients unable to 
reverse an early anti-inﬂ  ammatory phenotype by 3 to 4 
days are at increased risk of poor outcome [3]. An early 
anti-inﬂ   ammatory phenotype (possible CARS) is thus 
apparently not as concerning as prolonged immune sup-
pression (probably immunoparalysis). Unfortunately, the 
mecha  nisms or predispositions mediating the transition 
from CARS to immunoparalysis are currently unknown.
Th  e work by Giamarellos-Bourboulis and colleagues, 
and that of many other researchers, seeks to uncover the 
events surrounding sepsis-related immune system dys-
func  tion. By understanding the mechanisms involved, 
such as altered caspase-1 action, novel therapeutic 
targets may be identiﬁ  ed. Th  rough careful targeting of 
therapy to those patients with true immunoparalysis, the 
best chance for improved outcomes will be realized.
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